JMIRxMed JMIRx Med JMIRx Med 2563-6316 JMIR Publications Toronto, Canada v2i3e33496 27629825 10.2196/33496 Authors' Response to Peer Reviews Authors' Response to Peer Reviews Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study” Meinert Edward Jarrett Mark MBA, MD 1
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hofstra University 500 Hofstra University Hempstead, NY, 11549 United States 1 516 463 7516 mjarrett@northwell.edu
https://orcid.org/0000-0001-9252-3471 Licht Warren MD 1 https://orcid.org/0000-0001-8857-0814 Bock Kevin MHCDS, MD 1 https://orcid.org/0000-0002-8320-7482 Brown Zenobia MPH, MD 1 https://orcid.org/0000-0002-4514-4839 Hirsch Jamie MA, MSB, MD 1 https://orcid.org/0000-0001-9571-1275 Coppa Kevin BSc 2 https://orcid.org/0000-0001-9059-1235 Brar Rajdeep MD 1 https://orcid.org/0000-0003-0721-8179 Bello Stephen PA, MHCDS 2 https://orcid.org/0000-0002-3692-3734 Nash Ira MD 1 https://orcid.org/0000-0002-3979-8166 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hofstra University Hempstead, NY United States Northwell Health New Hyde Park, NY United States Corresponding Author: Mark Jarrett mjarrett@northwell.edu Jul-Sep 2021 27 9 2021 2 3 e33496 9 9 2021 9 9 2021 ©Mark Jarrett, Warren Licht, Kevin Bock, Zenobia Brown, Jamie Hirsch, Kevin Coppa, Rajdeep Brar, Stephen Bello, Ira Nash. Originally published in JMIRx Med (https://med.jmirx.org), 27.09.2021. 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.

 https://www.medrxiv.org/content/10.1101/2021.04.09.21255219v1 https://preprints.jmir.org/preprint/29638 https://med.jmirx.org/2021/3/e33499/ https://med.jmirx.org/2021/3/e29638/ infectious disease monoclonal antibody therapy COVID-19 experience therapy drug patient outcome risk efficacy approach treatment pandemic antibody immunotherapy immune therapy

This is the authors’ response to peer-review reports for “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study.”

Round 1 Review [<xref ref-type="bibr" rid="ref1">1</xref>]

Formatting in paper [2] changed as requested

Figures changed

Added suggested contextualization

Fortified Discussion

Although we added references and discussion of the inflammatory response to cytokines, it should be recognized that these antibodies work by neutralization of the virus, not by affecting cytokines.

 Anonymous Peer review of "Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study" JMIRx Med 2021 9 2 3 e33499 Jarrett M Licht W Bock K Brown Z Hirsch J Coppa K Brar R Bello S Nash I Early experience with neutralizing monoclonal antibody therapy for COVID-19: retrospective cohort survival analysis and descriptive study JMIRx Med 2021 9 2 3 e29638